Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that despite being the ninth largest state, Georgia ranks fourth in the number of untreated HIV patients in the United States.

"HIV prevalence is linked to ethnic/racial demographics as well as to urban/rural variations -- Georgia's larger than average black population drives Georgia's high prevalence of HIV," stated Jason LaBonte, Ph.D., vice president of new product development at Decision Resources. "Our epidemiologic model predicts that eight out of 1,000 people in Georgia have the disease versus the national average of five out of 1,000."

The new analytics tool entitled PatientFinder: HIV estimates that this high prevalence is compounded by Georgia's lower than average treatment rate for the disease (ranked 28th in the United States) which leaves a large number of HIV patients without drug therapy. Despite the abundance of untreated patients, however, Georgia remains a difficult target for pharmaceutical companies wishing to grow their patient base. Only 82 percent of the state's population has prescription drug insurance, which ranks 37th in the U.S.

Why Pharmaceutical Companies Need this Information

With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.

About PatientFinder

PatientFinder is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated. PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan statistical areas (MSAs) and provides:

  --  Disease-specific prevalence numbers for each U.S. state and MSA   --  Examination of treatment rates for the disease population to create       percent treated and percent untreated estimates by state and MSA   --  Unique analysis of the untreated population examined through a filter       of prescription (Rx) benefit coverage. The end result is an estimate       of how many patients are untreated but can afford therapy within each       territory - the true local measure of opportunity for pharmaceutical       companies    About Decision Resources 

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Natalia Morales                    Elizabeth Marshall   Decision Resources                 Decision Resources, Inc.   781-296-2691                       781-296-2563   nmorales@dresources.com            emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,
nmorales@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
781-296-2563, emarshall@dresources.com

An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe

View Now